contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nomination-committee-appointed-for-dicot-pharma-ab-1

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Dicot Pharma is developing the drug candidate LIB-01, which is expected to be a potency drug for the treatment of erectile dysfunction and premature ejaculation. Duration of action and fewer side effects are the main desired properties. Dicot's main strategy is to continuously evaluate industrial partnerships during the development of LIB-01 to take the drug candidate to commercialization.

Dicot Pharma

Uppsala, Sweden, October 30, 2025. In accordance with the decision of the Annual General Meeting, a Nomination Committee has been appointed in Dicot Pharma AB. The Nomination Committee consists...

<div class="mfn-preamble"><p><strong>Uppsala, Sweden, October 30, 2025. In accordance with the decision of the Annual General Meeting, a Nomination Committee has been appointed in Dicot Pharma AB. The Nomination Committee consists of Göran Beijer, Tore Robertsson and Torsten Söderberg.</strong></p></div><div class="mfn-body"><p>In accordance with the instruction for the Nomination Committee adopted by the Annual General Meeting, the members of Dicot Pharma's Nomination Committee shall be appointed by the three largest shareholders/owner groups in the company as of end of September 2025, who wish to appoint a member.</p><p>The Nomination Committee has now been appointed and consists of the following three members:</p><ul><li>Göran Beijer, appointed by Bertil Lindkvist</li><li>Tore Robertsson, representing Tor Finans AB</li><li>Torsten Söderberg, representing Syoto AB and own holding</li></ul><p>Försäkringsaktiebolaget Avanza Pension and Nordnet Pensionsförsäkring AB have both declined to appoint representatives.</p><p>Tore Robertsson has been appointed Chairman of the Nomination Committee and has asked the Chairman of the Board, Eva Sjökvist Saers, to act as convener. No fees shall be paid to the members of the Nomination Committee.</p><p>The Nomination Committee is responsible for preparing and presenting proposals for the Chairman of the Board, Board members, Board fees (divided between the Chairman, Board members and any committees), the Chairman of the AGM, auditors' fees and the election of auditors. The Nomination Committee's proposals are submitted in connection with the notice of the next Annual General Meeting.</p><p>Shareholders who wish to submit proposals to the Nomination Committee can do so by e-mail to <a rel="noopener" href="mailto:eva.sjokvist@saers.se">eva.sjokvist@saers.se</a>. For the Nomination Committee to be able to process proposals received in a constructive manner, these should be received by the Nomination Committee no later than December 19, 2025.</p><p>Dicot Pharma's Annual General Meeting 2025 will be held on Wednesday, May 6, 2026, at 17.00 in Uppsala.</p></div><div class="mfn-footer mfn-062ae1d44f10"><p><strong class="mfn-heading-1">For further information, please contact:</strong><br>Eva Sjökvist Saers, chairman of the board<br>Phone: +46 70 550 7371<br>E-mail: <a rel="noopener" href="mailto:eva.sjokvist@saers.se">eva.sjokvist@saers.se</a></p></div><div class="mfn-footer mfn-about mfn-e4bb507bc5ad"><p><strong class="mfn-heading-1">About Dicot Pharma AB</strong><br>Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma’s business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market.&nbsp;</p><p>Dicot Pharma is listed on Nasdaq First North and has approximately 16,300 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit <a rel="noopener" href="http://www.dicotpharma.com">www.dicotpharma.com</a>.</p><p><em>This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/1485aab9-0f7a-4167-861c-6c35e32b6a9c/nomination-committee-appointed-for-dicot-pharma-ab.pdf" class="mfn-generated mfn-primary">Nomination Committee appointed for Dicot Pharma AB</a></p></div>